| 04.04.24 | Headlands, Pfizer open 5th trial site; Clario buys ArtiQ

Brand Logo CRO A message from Yourway SAVE THE DATE (Dublin, Ireland | 6 June 2024 JOIN US FOR AN EXCLUSIVE EVENT: Global Clinical Trial Innovation, Challenges, and Perspectives Reserve your seat today b1V rq\VANS nnnnnnnnnnnnnnnnnnnnnnnnnnn THIS WEEK Apr 4, 2024 Headlands opens final clinical trial site in Pfizer diversity partnership - Clario buys AI firm ArtiQ, taps CEO to head AI strategy - Lindus launches ‘all-in-one’ CRO for respiratory clinical trials  A message from WACKER CHEMIE AG FEATURED HEADLANDS OPENS FINAL CLINICAL TRIAL SITE IN PFIZER DIVERSITY PARTNERSHIP By Helen Floersh Headlands Research has opened the fifth and final research site under its multi-year partnership with Pfizer to increase the diversity of participants in clinical trials. TOP STORIES CLARIO BUYS AI FIRM ARTIQ, TAPS CEO TO HEAD AI STRATEGY By Helen Floersh Clinical health tech company Clario has purchased ArtiQ, an artificial intelligence software developer that creates AI solutions for diagnosing and treating patients with respiratory diseases. As part of the deal, ArtiQ CEO and co-founder Marko Topalovic will continue running his company in addition to leading Clario’s overall AI strategy. LINDUS LAUNCHES ‘ALL-IN-ONE’ CRO FOR RESPIRATORY CLINICAL TRIALS By Helen Floersh Lindus Health has developed another full-service CRO package for a specific therapeutic area, this time geared toward clinical trials for drugs to treat respiratory diseases like COPD, asthma, and pulmonary hypertension. J&J TARGETS RARE MATERNAL-FETAL DISEASES: 'WE'RE GOING FOR THIS. NO ONE ELSE HAS.' By Gabrielle Masson More than 60 years after RhoGAM’s approval, Johnson & Johnson's Katie Abouzahr, M.D., is hoping to build off the pharma’s own legacy and bring another maternal fetal immunology treatment to market. A message from Bioduro-Sundia WEBINAR: UNLEASHING INNOVATION: A NEW OBESOGENIC NASH MODEL WITH HIGH CLINICALLY TRANSLATIONAL POWER Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! IN MAJOR STEP TOWARD THE CLINIC, RING’S HUMAN VIRAL VECTOR DELIVERS GENE THERAPY TO EYES OF MICE By Helen Floersh Ring Therapeutics’ hunt for new human viruses that can deliver gene therapies multiple times in a single patient appears to have landed on a viable candidate, new mouse data have suggested.  VERVE HALTS ENROLLMENT OF LEAD TRIAL AFTER GRADE 3 SIDE EFFECTS, PRIORITIZING NEXT-UP PCSK9 EDITOR By Max Bayer Verve has halted enrollment in a phase 1 study testing its lead asset after a patient experienced two sets of grade 3 side effects. The focus now is on a second PCSK9 base editor, VERVE-102. 'ONE-TWO PUNCH' OF EPIGENETIC CANCER DRUGS COULD KNOCK OUT COLORECTAL CANCER CELLS By Helen Floersh A low dose of a DNMT inhibitor with EZH2 inhibitors induced changes in cancer cells that would make them more vulnerable to the immune system. A new clinical trial will evaluate the finding in patients. #FIERCEMADNESS: THE BEST BIOTECH NAME TOURNAMENT—ELITE 8 RESULTS By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. #FIERCEMADNESS: VALUE-BASED CARE, PATIENT ENGAGEMENT REACH FINAL FOUR By Paige Minemyer The NCAA basketball tournament is officially underway, and the Fierce Healthcare team is hosting our annual #FierceMadness competition yet again. Fierce podcasts DON’T MISS AN EPISODE THE TOP LINE 'THE TOP LINE': THE TOP MONEY RAISERS IN BIOTECH This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. 'THE TOP LINE': A CLOSER LOOK AT EUROPEAN BIOTECH INVESTMENT IN 2024 'PODNOSIS': A CLOSER LOOK AT SOCIAL PRESCRIBING AND THE IMPACT OF THE ARTS ON OUR HEALTH A message from Genome Medical WEBINAR: PINPOINTING AND ACTIVATING QUALIFIED PARTICIPANTS FOR CLINICAL TRIALS Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now. RESOURCES Whitepaper ONCOLOGY MARKET OUTLOOK 2024 This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences Whitepaper GUIDANCE FOR BIOTECHS CHOOSING NEXT-GEN CONTRACT GMP/CMC LABS Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services INDUSTRY EVENTS Drug Development Boot Camp® VIRTUAL | Spring 2024 April 10-11, 2024 On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK UPCOMING FIERCE EVENTS 6-8 May Medical Affairs Strategic Summit East Jersey City, NJ 13-15 May Digital Pharma Engage Newport Beach, CA 14-15 May Pharma PR & Communications Summit West Newport Beach, CA 21-23 May Digital Pharma Innovation Week Free Virtual Event 8-9 Jul Pharma PR & Communications Summit East Jersey City, NJ View all events Brand Logo Linkedin LogoFacebook LogoTwitter LogoYoutube Logo  Connect Advertise Contact Subscriptions Contact Support Our team Senior Editor: Annalee Armstrong UK/EU Bureau Chief: James Waldron Publisher: Rebecca Willumson Group Sales Director: Angelique Alcover This email was sent to [email protected] as part of the Fierce Biotech email list. /\\f SRS RIS RO K/ %J&j& L\